Drugs by condition
Drugs approved for plaque psoriasis
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
62
Still marketed, NDA or BLA
Drug classes
14
Novel drugs
18
New molecular entities and new biologics
In development
28
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for plaque psoriasis.
- Icotyde (Icotrokinra Hydrochloride) · Janssen Biotech NovelPriority reviewMar 17, 2026
- Otezla (Apremilast) · Amgen INC OrphanAug 29, 2025
- Starjemza (Ustekinumab-Hmny) · Bio-Thera Solutions LTD May 22, 2025
- Otulfi (Ustekinumab-Aauz) · Fresenius Kabi USA Apr 30, 2025
- Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTD Apr 30, 2025
All approved drugs for plaque psoriasis, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 36 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Tumor Necrosis Factor Blocker (10)
- Cimzia Certolizumab Pegol · Ucb INC · 2008
- Enbrel Etanercept · Immunex · 1998
- Remicade Infliximab · Centocor INC · 1998
- Yusimry Adalimumab-Aqvh · Emerge Bioscience Pte LTD · 2021
- Avsola Infliximab-Axxq · Amgen INC · 2019
- Hadlima Adalimumab-Bwwd · Samsung Bioepis CO LTD · 2019
- Hyrimoz Adalimumab-Adaz · Sandoz INC · 2018
- Renflexis Infliximab-Abda · Samsung Bioepis CO LTD · 2017
- Amjevita Adalimumab-Atto · Amgen INC · 2016
- Inflectra Infliximab-Dyyb · Celltrion INC · 2016
Interleukin-12 Antagonist (9)
- Stelara Ustekinumab · Centocor Ortho Biotech INC · 2009
- Starjemza Ustekinumab-Hmny · Bio-Thera Solutions LTD · 2025
- Otulfi Ustekinumab-Aauz · Fresenius Kabi USA · 2025
- Pyzchiva Ustekinumab-Ttwe · Samsung Bioepis CO LTD · 2025
- Steqeyma Ustekinumab-Stba · Celltrion, Inc. · 2024
- Pyzchiva Ustekinumab-Ttwe · Samsung Bioepis CO LTD · 2024
- Wezlana Ustekinumab-Auub · Amgen INC · 2023
- Wezlana Ustekinumab-Auub · Amgen INC · 2023
- Stelara Ustekinumab · Janssen Biotech · 2016
Interleukin-23 Antagonist (4)
Phosphodiesterase 4 Inhibitor (4)
Vitamin D Analog (4)
Interleukin-17A Antagonist (3)
Retinoid (3)
Calcineurin Inhibitor Immunosuppressant (2)
Tyrosine Kinase 2 Inhibitor (1)
- Sotyktu Deucravacitinib · Bristol · 2022
Aryl Hydrocarbon Receptor Agonist (1)
- Vtama Tapinarof · Organon LLC · 2022
Interleukin-17 Receptor A Antagonist (1)
- Siliq Brodalumab · Valeant Luxembourg · 2017
Corticosteroid (1)
- Topicort Desoximetasone · Sun Pharma Canada · 2013
Vitamin D3 Analog (1)
- Vectical Calcitriol · Galderma Labs Lp · 2009
Class not listed in FDA's data (18)
- Icotyde Icotrokinra Hydrochloride · Janssen Biotech · 2026
- Bimzelx Bimekizumab-Bkzx · Ucb INC · 2023
- Humira Adalimumab · Abbvie INC · 2002
- Imuldosa Ustekinumab-Srlf · Accord Biopharma Inc. · 2024
- Selarsdi Ustekinumab-Aekn · Alvotech USA INC · 2024
- Simlandi Adalimumab-Ryvk · Alvotech USA INC · 2024
- Idacio Adalimumab-Aacf · Fresenius Kabi USA · 2024
- Yuflyma Adalimumab-Aaty · Celltrion · 2023
- Hulio Adalimumab-Fkjp · Mylan Pharms INC · 2020
- Abrilada Adalimumab-Afzb · Pfizer INC · 2019
- Bryhali Halobetasol Propionate · Bausch · 2018
- Impoyz Clobetasol Propionate · Primus Pharms · 2017
- Cyltezo Adalimumab-Adbm · Boehringer Ingelheim · 2017
- Sernivo Betamethasone Dipropionate · Primus Pharms · 2016
- Ultravate Halobetasol Propionate · Lacer Pharma · 2015
- Enstilar Betamethasone Dipropionate, Calcipotriene · Leo Pharma As · 2015
- Taclonex Betamethasone Dipropionate, Calcipotriene, Calcipotriene Hydrate · Leo Pharma As · 2008
- Taclonex Betamethasone Dipropionate, Calcipotriene · Leo Pharma As · 2006
Drugs in development for plaque psoriasis
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- EnvudeucitinibPhase 34 trials
Alumis Inc · Plaque Psoriasis, SLE
- ICP-332Phase 34 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- ICP-488Phase 33 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Plaque Psoriasis Patients, Primary Sjögren's Syndrome, Cutaneous Lupus Erythematosus (CLE)
- SHR-1314Phase 33 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Active Non-radiographic Axial Spondyloarthritis, Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis
- CMS-D001Phase 32 trials
Dermavon Holdings Limited · Moderate to Severe Plaque Psoriasis, Moderate to Severe Atopic Dermatitis
- HS-20137QX004NPhase 32 trials
Hansoh BioMedical R&D Company · Moderate-to-severe Plaque Psoriasis
- NetakimabPhase 32 trials
Biocad · Plaque Psoriasis
- PicankibartPhase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriatic Arthritis, Plaque Psoriasis
- piclidenosonPhase 32 trials
Can-Fite BioPharma · Plaque Psoriasis, Lowe Syndrome
- SYHX1901Phase 32 trials
CSPC Ouyi Pharmaceutical Co., Ltd. · Moderate to Severe Plaque Psoriasis, Severe Alopecia Areata
- WD-890Phase 32 trials
Zhejiang Wenda Pharma Technology LTD. · Brief Description of Focus of Study, Moderate to Severe Plaque Psoriasis
- Blinded EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
- GNR-068Phase 31 trial
AO GENERIUM · Plaque Psoriasis
- Open-Label EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
- QL2106Phase 31 trial
Qilu Pharmaceutical Co., Ltd. · Plaque Psoriasis
- SHR-1139Phase 25 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Moderate to Severe Plaque Psoriasis, Palmoplantar Pustulosis of Adults, Pyoderma Gangrenosum
- ORKA-002Phase 23 trials
Oruka Therapeutics, Inc. · Plaque Psoriasis, Hidradenitis Suppurativa (HS)
More on plaque psoriasis: recruiting trials · published research
Related in immunology and inflammation: Rheumatoid arthritis · Psoriatic arthritis · Atopic dermatitis (eczema) · Crohn's disease · Ulcerative colitis · Ankylosing spondylitis · Lupus (SLE) · Hidradenitis suppurativa · Chronic hives (urticaria) · Alopecia areata
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.